Following a limited submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Perampanel (Fycompa®) is recommended as an option for restricted use within NHS Wales. Perampanel (Fycompa®) should be restricted to treatment of patients whose seizures are still uncontrolled with the first adjunctive therapy, within its licensed indication for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients from 4 to < 12 years of age. Perampanel (Fycompa®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | perampanel (Fycompa®) | ||
| Formulation | 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg film-coated tablets; 0.5 mg/ml oral suspension | ||
| Reference number | 4770 | ||
| Indication | Adjunctive treatment of partial-onset seizures (POS) with or without secondarily generalised seizures in patients from 4 to < 12 years of age |
||
| Company | Eisai Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Limited | ||
| Status | Recommended with restrictions | ||
| Advice number | 0821 | ||
| NMG meeting date | 14/04/2021 | ||
| AWMSG meeting date | 19/05/2021 | ||
| Date of issue | 24/05/2021 | ||
| Commercial arrangement | WPAS | ||